Dosage of Capecitabine and Cyclophosphamide Combination Therapy in Patients with Metastatic Breast Cancer

Background: Capecitabine is a highly effective and well-tolerated treatment for metastatic breast cancer (MBC) and extends survival when combined with docetaxel. Capecitabine and cyclophosphamide are orally administered and have preclinical synergy and non-overlapping toxicities. Patients and Method...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Anticancer research 2007-03, Vol.27 (2), p.1009-1013
Hauptverfasser: OHNO, Shinji, MITSUYAMA, Shoshu, TAMURA, Kazuo, NISHIMURA, Reiki, TANAKA, Maki, HAMADA, Yuzo, KUROKI, Shoji
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background: Capecitabine is a highly effective and well-tolerated treatment for metastatic breast cancer (MBC) and extends survival when combined with docetaxel. Capecitabine and cyclophosphamide are orally administered and have preclinical synergy and non-overlapping toxicities. Patients and Methods: Sixteen pretreated MBC patients received escalating doses of oral capecitabine 628 to 829 mg/m 2 twice daily (bid) plus oral cyclophosphamide 33 to 50 mg/m 2 bid, on days 1 to 14 every 21 days. Results: Among the ten patients receiving capecitabine/cyclophosphamide 829/33 mg/m 2 bid on days 1 to 14, two experienced dose-limiting toxicities (DLT, treatment delay >1 week due to grade 2 leukopenia). Because neither patient developed further grade >1 toxicity and none of the patients experienced grade 3/4 toxicities or further DLTs, this dose level is the recommended regimen, producing partial responses in two of five evaluable patients. Conclusion: The recommended all oral capecitabine/cyclophosphamide combination regimen is well tolerated and active in MBC, and is being evaluated in a phase II study in anthracycline-pretreated MBC.
ISSN:0250-7005
1791-7530